64 Cu 2+ Complexes of Tripodal Amine Ligands' In Vivo Tumor and Liver Uptakes and Intracellular Cu Distribution in the Extrahepatic Bile Duct Carcinoma Cell Line TFK-1: A Basic Comparative Study.
Mitsuhiro ShinadaMasashi TakahashiChika IgarashiHiroki MatsumotoFukiko HiharaTomoko TachibanaMasakazu OikawaHisashi SuzukiMing-Rong ZhangTatsuya HigashiHiroaki KuriharaYukie YoshiiYoshihiro DoiPublished in: Pharmaceuticals (Basel, Switzerland) (2024)
Copper (Cu) is a critical element for cancer cell proliferation and considerably accumulates in the nucleus. 64 Cu 2+ is an anticancer radiopharmaceutical that targets the copper requirement of cancer cells. However, intravenously injected 64 Cu 2+ ions primarily accumulate in the liver. Ligand complexation of 64 Cu 2+ may be a promising method for increasing tumor delivery by reducing liver uptake. In this study, we used three tripodal amine ligands [tris(2-aminoethyl)amine (Tren), diethylenetriamine (Dien), and tris(2-pyridylmethyl)amine (TPMA)] to enclose 64 Cu 2+ ions and compared their in vivo tumor and liver uptakes using a tumor-bearing xenograft mouse model of the extrahepatic bile duct carcinoma cell line TFK-1. We examined intracellular Cu distribution using microparticle-induced X-ray emission (micro-PIXE) analysis of these compounds. 64 Cu 2+ -Tren and 64 Cu 2+ -Dien showed higher tumor uptake than 64 Cu 2+ -TPMA and 64 Cu 2+ ions in TFK-1 tumors. Among the three 64 Cu 2+ complexes and 64 Cu 2+ ions, liver uptake was inversely correlated with tumor uptake. Micro-PIXE analysis showed that in vitro cellular uptake was similar to in vivo tumor uptake, and nuclear delivery was the highest for 64 Cu 2+ -Tren. Conclusively, an inverse correlation between tumor and liver uptake was observed using three 64 Cu 2+ complexes of tripodal amine ligands and 64 Cu 2+ ions. These results provide useful information for the future development of anticancer 64 Cu radiopharmaceuticals.